Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Abhinav V, Kurada"'
Publikováno v:
Scientific Reports, Vol 12, Iss 1, Pp 1-15 (2022)
Abstract Multiple sclerosis (MS) is a heterogeneous autoimmune disease for which diagnosis continues to rely on subjective clinical judgment over a battery of tests. Proton magnetic resonance spectroscopy (1H MRS) enables the noninvasive in vivo dete
Externí odkaz:
https://doaj.org/article/a35fffef56294263868393289950009d
Autor:
Kelley M. Swanberg, Hetty Prinsen, Katherine DeStefano, Mary Bailey, Abhinav V. Kurada, David Pitt, Robert K. Fulbright, Christoph Juchem
Publikováno v:
NMR in Biomedicine. 34
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7c65a39b5f70e05c5cd6541a8bedc546
https://doi.org/10.1002/nbm.4634
https://doi.org/10.1002/nbm.4634
Publikováno v:
Scientific reports. 12(1)
Multiple sclerosis (MS) is a heterogeneous autoimmune disease for which diagnosis continues to rely on subjective clinical judgment over a battery of tests. Proton magnetic resonance spectroscopy (
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::4694621f74489765de1e18e36e545deb
https://pubmed.ncbi.nlm.nih.gov/35974117
https://pubmed.ncbi.nlm.nih.gov/35974117
Autor:
Katherine DeStefano, Hetty Prinsen, David Pitt, Christoph Juchem, Mary Lou P. Bailey, Robert K. Fulbright, Kelley M. Swanberg, Abhinav V. Kurada
Publikováno v:
NMR in Biomedicine. 34
The pathophysiology of progressive multiple sclerosis remains elusive, significantly limiting available disease-modifying therapies. Proton MRS (1 H-MRS) enables in vivo measurement of small molecules implicated in multiple sclerosis, but its applica
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e203c560274386b465c6a35796ed495b
https://doi.org/10.1002/nbm.4590
https://doi.org/10.1002/nbm.4590
Autor:
Abhinav V. Kurada, Tarun Srinivasan, Jonathan Bidwell, Sarah P. Hammond, Adriana Ulate-Campos
Publikováno v:
Seizure. 66:61-69
Objective This study characterizes the current capabilities of seizure detection device (SDD) technology and evaluates the fitness of these devices for use in anti-seizure medication (ASM) clinical trials. Methods Through a systematic literature revi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bcafa6299eb78d1cdd8a2cf573dc0e45
https://doi.org/10.1016/j.seizure.2019.02.007
https://doi.org/10.1016/j.seizure.2019.02.007